In addition, many perfectly recognized adverse prognostic markers, like U-CLL, ATM aberrations or NOTCH1/BIRC3 mutations, misplaced their destructive result in patients treated with VO. The one aspect that remained predictive of the shorter progression-no cost survival In this particular cohort of patients was TP53 aberrations.112 Eventually, the a